US FDA News: FDA Approves First Treatment for Adult Onset Still’s Disease, a Severe and Rare Disease

FDA approved Ilaris (canakinumab) injection for the treatment of Active Still’s disease, including Adult-Onset Still’s Disease (AOSD). Ilaris was previously approved for Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.
Read more: FDA Approves First Treatment for Adult Onset Still’s Disease, a Severe and Rare Disease